2024
945TiP JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC)
Machiels J, Burtness B, Harrington K, Saba N, Tahara M, Crossman T, Hua L, Perera A, Theti D, Zografos E, Siu L. 945TiP JADE: A phase (ph) III study to evaluate dostarlimab vs placebo (PBO) as sequential therapy after chemoradiation (CRT) in patients (pts) with locally advanced unresected head and neck squamous cell carcinoma (LA-HNSCC). Annals Of Oncology 2024, 35: s655. DOI: 10.1016/j.annonc.2024.08.2145.Peer-Reviewed Original Research
2020
Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412
Machiels JP, Tao Y, Burtness B, Tahara M, Licitra L, Rischin D, Waldron J, Simon C, Gregoire V, Harrington K, Alves GV, Lima I, Pointreau Y, Hughes B, Aksoy S, Hetnal M, Ge JY, Brown H, Cheng J, Bidadi B, Siu LL. Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412. Future Oncology 2020, 16: 1235-1243. PMID: 32490686, DOI: 10.2217/fon-2020-0184.Peer-Reviewed Original ResearchConceptsNeck squamous cell carcinomaPhase III trialsSquamous cell carcinomaChemoradiation therapyAdvanced headIII trialsCell carcinomaImmune checkpoint inhibitor pembrolizumabLarge phase III trialsCheckpoint inhibitor pembrolizumabUse of pembrolizumabCurrent treatment guidelinesAdvanced HNSCCAdvanced diseaseMaintenance therapyMetastatic HNSCCTreatment guidelinesMaintenance treatmentMultimodal treatmentPembrolizumabPatientsAntitumor activityIB dataChemoradiationHNSCCAdjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer
Saeed NA, Kelly JR, Deshpande HA, Bhatia AK, Burtness BA, Judson BL, Mehra S, Edwards HA, Yarbrough WG, Peter PR, Holt EH, Decker RH, Husain ZA, Park HS. Adjuvant external beam radiotherapy for surgically resected, nonmetastatic anaplastic thyroid cancer. Head & Neck 2020, 42: 1031-1044. PMID: 32011055, DOI: 10.1002/hed.26086.Peer-Reviewed Original ResearchConceptsAnaplastic thyroid cancerLonger OSAdjuvant EBRTThyroid cancerAdjuvant external beam radiotherapyNational Cancer DatabaseExternal beam radiotherapyConcurrent chemoradiationConcurrent chemotherapyImproved survivalMedian ageCancer DatabaseRetrospective analysisBeam radiotherapyEBRTChemotherapyPatientsCancerUVAChemoradiationResectionRadiotherapy
2018
1121TiP KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)
Machiels J, Licitra L, Tao Y, Yen C, Rischin D, Waldron J, Burtness B, Gregoire V, Agarwala S, Yorio J, Delord J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. 1121TiP KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC). Annals Of Oncology 2018, 29: viii398. DOI: 10.1093/annonc/mdy287.078.Peer-Reviewed Original ResearchPembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study.
Machiels J, Licitra L, Tao Y, Yen C, Rischin D, Waldron J, Burtness B, Gregoire V, Agarwala S, Yorio J, Delord J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. Pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma: The phase 3 KEYNOTE-412 study. Journal Of Clinical Oncology 2018, 36: tps6094-tps6094. DOI: 10.1200/jco.2018.36.15_suppl.tps6094.Peer-Reviewed Original Research
2017
96TiP Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
Machiels J, Yen C, Licitra L, Rischin D, Waldron J, Burtness B, Gregoire V, Tao Y, Yorio J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. 96TiP Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Annals Of Oncology 2017, 28: xi28. DOI: 10.1093/annonc/mdx711.077.Peer-Reviewed Original Research373TiP KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
Yen C, Machiels J, Licitra L, Rischin D, Waldron J, Burtness B, Gregoire V, Tao Y, Yorio J, Aksoy S, Ikeda S, Hong R, Ge J, Brown H, Bidadi B, Siu L. 373TiP KEYNOTE-412: Phase 3 trial of pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Annals Of Oncology 2017, 28: x110. DOI: 10.1093/annonc/mdx665.036.Peer-Reviewed Original Research1105TiP Pembrolizumab plus chemoradiation (CRT) for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Phase 3 KEYNOTE-412 trial
Machiels J, Licitra L, Rischin D, Waldron J, Burtness B, Grégoire V, Shekar T, Brown H, Cheng J, Siu L. 1105TiP Pembrolizumab plus chemoradiation (CRT) for the treatment of locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Phase 3 KEYNOTE-412 trial. Annals Of Oncology 2017, 28: v392. DOI: 10.1093/annonc/mdx374.056.Peer-Reviewed Original Research
2016
Comparison of Upfront Surgery Versus Chemoradiation for cT1-2 N1-2b Oropharynx Squamous Cell Carcinoma Based on Human Papillomavirus Status
Kelly J, Park H, An Y, Decker R, Contessa J, Yarbrough W, Burtness B, Judson B, Husain Z. Comparison of Upfront Surgery Versus Chemoradiation for cT1-2 N1-2b Oropharynx Squamous Cell Carcinoma Based on Human Papillomavirus Status. International Journal Of Radiation Oncology • Biology • Physics 2016, 96: e327. DOI: 10.1016/j.ijrobp.2016.06.1451.Peer-Reviewed Original Research
2014
Increased Time From Neoadjuvant Chemoradiation to Surgery Is Associated With Higher Pathologic Complete Response Rates in Esophageal Cancer
Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE. Increased Time From Neoadjuvant Chemoradiation to Surgery Is Associated With Higher Pathologic Complete Response Rates in Esophageal Cancer. The Annals Of Thoracic Surgery 2014, 99: 270-276. PMID: 25440267, PMCID: PMC4284823, DOI: 10.1016/j.athoracsur.2014.08.033.Peer-Reviewed Original ResearchConceptsPathologic complete response rateComplete response rateHigher pathologic complete response rateNeoadjuvant chemoradiationResponse rateEsophageal cancerNeoadjuvant chemoradiation treatmentCompletion of chemoradiationTiming of surgeryLength of stayOperative stayChemoradiation treatmentBlood lossPathologic responseSurgery intervalSurgical morbidityCancer sitesChemoradiationMorbidity dataSurgeryPatientsInterval groupTreatment factorsEsophagectomyStayTrends and variations in the use of adjuvant therapy for patients with head and neck cancer
Chen MM, Roman SA, Yarbrough WG, Burtness BA, Sosa JA, Judson BL. Trends and variations in the use of adjuvant therapy for patients with head and neck cancer. Cancer 2014, 120: 3353-3360. PMID: 25042524, DOI: 10.1002/cncr.28870.Peer-Reviewed Original ResearchConceptsAdjuvant therapyAdverse pathologic featuresAdjuvant chemoradiationPathologic featuresNeck cancerNational Comprehensive Cancer Network guidelinesNational Cancer Data BaseMedicare/Medicaid insuranceImproved overall survivalHospital-level factorsCox multivariate regressionLog-rank testMultivariate logistic regressionForm of radiotherapyQuality of careAdjuvant radiotherapyOverall survivalMedicaid insuranceNetwork guidelinesCancer CenterLaryngeal cancerPractice patternsChemoradiationOral cavityPatientsInduction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303)
Wanebo HJ, Lee J, Burtness BA, Ridge JA, Ghebremichael M, Spencer SA, Psyrri D, Pectasides E, Rimm D, Rosen FR, Hancock MR, Tolba KA, Forastiere AA. Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303). Annals Of Oncology 2014, 25: 2036-2041. PMID: 25009013, PMCID: PMC4176450, DOI: 10.1093/annonc/mdu248.Peer-Reviewed Original ResearchConceptsEvent-free survivalStage III/IV headResponse/survivalInduction therapyComplete responseStage III/IV HNSCCNeck squamous cell carcinomaPrimary site biopsiesTreatment-related deathsPathologic complete responseNeck squamous cancerSquamous cell carcinomaProtein expression statusEligible patientsSite biopsiesOverall survivalCell carcinomaPromising survivalSquamous cancerDisease progressionChemoradiationRadiation therapyPatientsWeek 9Cetuximab
2012
Multi-Modality Therapy for Cancer of the Esophagus and GE Junction
Tejani MA, Burtness BA. Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. Current Treatment Options In Oncology 2012, 13: 390-402. PMID: 22592595, DOI: 10.1007/s11864-012-0193-5.Peer-Reviewed Original ResearchConceptsGastroesophageal junctionNeoadjuvant platinum-based chemotherapyPostoperative adjuvant chemotherapyPlatinum-based chemotherapyIncidence of adenocarcinomaSubgroup of patientsHigh mortality rateAdjuvant chemotherapyOpinion statementCancersInduction chemotherapyNeoadjuvant treatmentPreoperative chemoradiationDistant recurrenceModality therapySystemic therapyDistal esophagusAdvanced tumorsPredictive biomarkersMortality rateTherapeutic outcomesChemotherapyEsophagusTherapyTherapy deliveryChemoradiation
2011
Maximizing the Effect of Neoadjuvant Chemoradiation in Patients with Borderline Resectable Pancreatic Cancer
Sopka D, Chun Y, Cohen S, Zhu F, Milestone B, Cooper H, Freedman G, Burtness B, Hoffman J, Meyer J. Maximizing the Effect of Neoadjuvant Chemoradiation in Patients with Borderline Resectable Pancreatic Cancer. International Journal Of Radiation Oncology • Biology • Physics 2011, 81: s335. DOI: 10.1016/j.ijrobp.2011.06.1804.Peer-Reviewed Original Research
2010
Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303).
Wanebo H, Ghebremichael M, Burtness B, Ridge J, Spencer S, Rosen F, Hancock M, Tolba K, Forastiere A. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: Primary site organ preservation and disease control at 2 years (ECOG, E2303). Journal Of Clinical Oncology 2010, 28: 5513-5513. DOI: 10.1200/jco.2010.28.15_suppl.5513.Peer-Reviewed Original Research